- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01597505
Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)
July 15, 2019 updated by: Cubist Pharmaceuticals LLC
A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea
606 participants with Clostridium Difficile Associated Diarrhea (CDAD) participated in this study and received either oral vancomycin or CB-183,315 (surotomycin) in a blinded fashion.
Treatment lasted for 10 days and participants were followed up for at least 40 days and a maximum of 100 days.
The purpose of this study was to evaluate how well surotomycin treats CDAD as compared to vancomycin.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
606
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
To be included in this study, participants must:
- Sign a consent form;
- Be >= 18 and < 90 years of age;
- Have diarrhea, at least 3 times during one day, or 200 mL or liquid stool if using a rectal device;
- Test positive for Clostridium difficile;
- If female, must not be pregnant or nursing and take appropriate measures to not get pregnant during the study.
Participants will not be allowed into the study if they:
- Have toxic megacolon and/or known small bowel ileus;
- Have received treatment with intravenous immune globulin (IVIG) within the past 30 days;
- Have received treatment with a fecal transplant within 7 days, and/or if the doctor anticipates to give the participant a fecal transplant during the study;
- Have received a certain amount of antibacterial therapy specific for current CDAD, unless it is not working;
- Have received an investigational vaccine against C. difficile;
- Have received an investigational product containing monoclonal antibodies against toxin A or B within 180 days;
- Had more than 2 episodes of CDAD within 90 days;
- Had major gastrointestinal (GI) surgery (i.e. significant bowel resection) within 3 months (this does not include appendectomy or cholecystectomy);
- Have history of prior inflammatory bowel disease: ulcerative colitis, Crohn's disease, or microscopic colitis;
- Are unable to discontinue loperamide, diphenoxylate/atropine, or cholestyramine during the duration of the study;
- Are unable to discontinue opiate treatment unless on a stable dose;
- Has known positive stool cultures for other enteropathogens including but not limited to Salmonella, Shigella, and Campylobacter;
- Had stool studies positive for pathogenic ova and/or parasites;
- Have an intolerance or hypersensitivity to daptomycin and/or vancomycin;
- Have life-threatening illness at the time of enrollment;
- Have poor concurrent medical risks that in the opinion of the Investigator the participant should not enroll;
- Have received an investigational drug or participated in any experimental procedure within 1 month;
- Have human immunodeficiency virus (HIV), a cluster of differentiation 4 (CD4) < 200 cells/mm3 within 6 months of start of study therapy;
- Anticipate that certain antibacterial therapy for a non-CDAD infection will be required for > 7 days;
- Are unable to discontinue Saccharomyces or similar probiotic;
- Are on a concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy;
- Are unable to comply with the protocol requirements;
- Have any condition that, in the opinion of the Investigator, might interfere;
- Are not expected to live for less than 8 weeks.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Surotomycin
250 mg Surotomycin over- encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg; and Placebo over encapsulated tablet administered orally, twice daily for 10 days
|
250 mg Surotomycin over-encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg, for 10 days
Other Names:
Placebo for Surotomycin over-encapsulated tablet administered orally, twice daily for 10 days
|
Active Comparator: Vancomycin
125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days
|
125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT)
Time Frame: Up to 13 days
|
A clinical outcome of cure at EOT was determined by resolution of diarrhea, defined as ≤ 2 loose stools per 24-hour period for at least 2 consecutive days and the lack of need for additional antibiotics to treat the current CDAD episode after completion of the study treatment period.
Participants requiring a collection device were considered to have resolution of diarrhea when the volume of stool (over a 24-hour period) was decreased by 75% as compared to baseline or the participant was no longer passing liquid stool.
The estimated adjusted percentage was a weighted average across all strata, constructed using Mehrotra-Railkar continuity-corrected minimum risk (MRc) stratum weights.
|
Up to 13 days
|
Percentage of Participants With at Least One Adverse Event (AE)
Time Frame: Up to Day 50
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
AEs may be new events or may be pre-existing conditions that have become aggravated or have worsened in severity or frequency; or may be clinically significant changes from baseline in physical examination, laboratory tests, or other diagnostic investigation (e.g.
laboratory results, x-ray findings).
|
Up to Day 50
|
Percentage of Participants With at Least One Serious Adverse Event (SAE)
Time Frame: Up to Day 50
|
A SAE is any adverse experience occurring at any dose that results in any of the following outcomes: death; a life-threatening experience, referring to a situation in which the participant was at risk of death at the time of the event, requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; or is considered to be an important medical event.
|
Up to Day 50
|
Percentage of Participants Who Discontinued Treatment Due to an AE
Time Frame: Up to Day 13
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
AEs may be new events or may be pre-existing conditions that have become aggravated or have worsened in severity or frequency; or may be clinically significant changes from baseline in physical examination, laboratory tests, or other diagnostic investigation (e.g.
laboratory results, x-ray findings).
|
Up to Day 13
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Clinical Response Over Time
Time Frame: Up to Day 41
|
Clinical response over time as measured by those without treatment failure, recurrence, death, or lost to follow-up, measured as the number of participants without failure events (survivors) through the end of therapy (reported for Day 14) and from end of therapy to Day 40 (reported for Day 41).
|
Up to Day 41
|
Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study
Time Frame: Up to Day 50
|
Sustained clinical response at the end of study was achieved by participants who had a clinical outcome of cure at the end of treatment (Days 40-50) and did not experience a recurrence of CDAD, did not die, were not lost to follow-up, and did not have end of study visit prior to Day 40.
The estimated adjusted percentage was a weighted average across all strata, constructed using MRc stratum weights.
|
Up to Day 50
|
Adjusted Percentage of Participants With Sustained Clinical Response at Day 24
Time Frame: Day 24
|
Sustained clinical response at Day 24 was defined as participants who had a clinical outcome of cure at Day 24, who did not experience a recurrence of CDAD, did not die, were not lost to follow-up.
Only the first failure event was counted per participant.
The estimated adjusted percentage was a weighted average across all strata, constructed using MRc stratum weights.
|
Day 24
|
Adjusted Percentage of Participants With Recurrence of CDAD at End of Study
Time Frame: Up to Day 50
|
Participants with recurrences were defined as those who were cured at the end of therapy and had a recurrence or were lost to follow-up, died or had a Day 40 -50 contact prior to Day 40.
The estimated adjusted percentage was a weighted average across all strata, constructed using MRc stratum weights.
|
Up to Day 50
|
Time to Resolution of Diarrhea
Time Frame: Up to Day 13
|
Time to resolution of diarrhea with =< 2 unformed bowel movements (UBM) per 24-hour period was calculated as the date/time of last UBM minus the date/time of the first dose of study drug.
|
Up to Day 13
|
Time to Reappearance of Diarrhea From End of Treatment to the End of Study
Time Frame: Up to Day 50
|
Time to reappearance of diarrhea with >= 3 UBM per 24-hour period was calculated as the last date/time of study drug dose to the date/time of first reappearance of 3 or more UBMs among participants who were cured at end of treatment.
|
Up to Day 50
|
Adjusted Percentage of Participants With a Clinical Response at the End of Treatment for Infections Deemed to be Caused by the C. Difficile BI/NAP1/027 Strain at Baseline
Time Frame: Up to Day 13
|
Clinical response corresponded to a clinical outcome of cure at the end of treatment, and was achieved by participants with infections deemed to be caused by the C. difficile BI/NAP1/027 strain at baseline, who did not fail treatment, did not die, or were not lost to follow-up at the end of treatment.
The estimated adjusted percentage was a weighted average across all strata, constructed using MRc stratum weights.
|
Up to Day 13
|
Adjusted Percentage of Participants Per Protocol 1 Population With a Clinical Response at the End of Treatment
Time Frame: Up to Day 13
|
Clinical response corresponded to a clinical outcome of cure at the end of treatment, and was achieved by participants who did not fail treatment, did not die, or were not lost to follow-up at the end of treatment.
The estimated adjusted percentage was a weighted average across all strata, constructed using MRc stratum weights.
|
Up to Day 13
|
Adjusted Percentage of Participants With a Sustained Clinical Response at the End of Study for Infections Deemed to be Caused by the C. Difficile BI/NAP1/027 Strain at Baseline
Time Frame: Up to Day 50
|
Sustained clinical response at the end of study was achieved by participants with infections deemed to be caused by the C. difficile BI/NAP1/027 strain at baseline, who had a clinical outcome of cure at the end of treatment (Day 13) and did not experience a recurrence of CDAD, did not die, were not lost to follow-up, and did not have end of study visit prior to Day 40.
The estimated adjusted percentage was a weighted average across all strata, constructed using MRc stratum weights.
|
Up to Day 50
|
Adjusted Percentage of Participants From the Per Protocol 2 Population With a Sustained Clinical Response at the End of Study
Time Frame: Up to Day 50
|
Sustained clinical response at the end of study was achieved by participants who had a clinical outcome of cure at the end of treatment (Days 40-50) and did not experience a recurrence of CDAD, did not die, were not lost to follow-up, and did not have end of study visit prior to Day 40.
Only the first failure event per participant was counted.
The estimated adjusted percentage was a weighted average across all strata, constructed using MRc stratum weights.
|
Up to Day 50
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Boix V, Fedorak RN, Mullane KM, Pesant Y, Stoutenburgh U, Jin M, Adedoyin A, Chesnel L, Guris D, Larson KB, Murata Y. Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection. Open Forum Infect Dis. 2017 Jan 19;4(1):ofw275. doi: 10.1093/ofid/ofw275. eCollection 2017 Winter.
- Cheknis A, Devaris D, Chesnel L, Dale SE, Nary J, Sambol SP, Citron DM, Goering RV, Johnson S. Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities. J Antimicrob Chemother. 2020 Nov 1;75(11):3120-3125. doi: 10.1093/jac/dkaa297.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 16, 2012
Primary Completion (Actual)
March 20, 2015
Study Completion (Actual)
March 20, 2015
Study Registration Dates
First Submitted
May 10, 2012
First Submitted That Met QC Criteria
May 11, 2012
First Posted (Estimate)
May 14, 2012
Study Record Updates
Last Update Posted (Actual)
July 23, 2019
Last Update Submitted That Met QC Criteria
July 15, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4261-005
- LCD-CDAD-10-07 (Other Identifier: Cubist Study Number)
- MK-4261-005 (Other Identifier: Merck Protocol Number)
- 2012-000252-34 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clostridium Difficile Infection
-
Vedanta Biosciences, Inc.CompletedClostridium Difficile Infection | Clostridium Difficile Infection Recurrence | Clostridium Difficile | CDI | Clostridioides Difficile Infection | Clostridioides Difficile | Clostridioides Difficile Infection RecurrenceUnited States, Canada
-
Vedanta Biosciences, Inc.Not yet recruitingClostridium Difficile Infection Recurrence | Recurrent Clostridium Difficile Infection | Clostridium Difficile | Diarrhea Infectious | CDI | Clostridium Difficile Infections | Clostridioides Difficile Infection | C.Difficile Diarrhea | Clostridioides Difficile Infection Recurrence | C. Diff Infection
-
University of PennsylvaniaTerminatedSevere Clostridium Difficile Infection | Severe-Complicated/Fulminant Clostridium Difficile InfectionUnited States
-
Mikrobiomik Healthcare Company S.L.CompletedRecurrent Clostridium Difficile Infection | Primary Clostridium Difficile InfectionSpain
-
University Health Network, TorontoTerminatedRecurrent Clostridium Difficile Infection | Laboratory Confirmed Clostridium Difficile InfectionCanada
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences Institute; North Carolina...CompletedClostridium DifficileUnited States
-
University of Wisconsin, MadisonAgency for Healthcare Research and Quality (AHRQ)Enrolling by invitationClostridium Difficile Infection | Clostridium Difficile | C Difficile ColitisUnited States
-
MJM BontenUniversiteit Antwerpen; Universitätsklinikum Köln; Da VolterraCompletedClostridium DifficileGermany, Spain, France, Greece, Netherlands, Romania
-
Astellas Pharma Europe Ltd.Cubist Pharmaceuticals LLCTerminatedClostridium DifficileSpain, France, Germany, Greece, Denmark, Austria, Poland
-
Chinese University of Hong KongUnknownClostridium Difficile Infection | Clostridium DifficileHong Kong
Clinical Trials on Surotomycin
-
Merck Sharp & Dohme LLCCompletedClostridium Difficile Associated Diarrhea (CDAD)
-
Merck Sharp & Dohme LLCCompletedClostridium Difficile Associated Diarrhea (CDAD)
-
Cubist Pharmaceuticals LLCCompletedClostridium Difficile Infection